New Drug Combo Significantly Reduces Breast Cancer Progression Risk
TL;DR
A Phase 3 study shows that combining Gilead's Trodelvy with Merck's Keytruda significantly reduces tumor progression risk in women with aggressive triple-negative breast cancer, potentially leading to new treatment options.
- Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows statnews.com
- Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial Reuters
- ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC OncLive
- ASCO: Gilead bolsters Trodelvy in triple-negative breast cancer with practice-changing Keytruda combo win Fierce Pharma
- Blockbuster breast cancer drug combination will change the way cancer is treated New York Post
Want the full story? Read the original reporting
Read on statnews.com